GEN Exclusives

More »

GEN News Highlights

More »
Jun 21, 2007

LAB Licenses Breakthrough Cancer Pain Therapy to Janssen Pharmaceutica in Europe and Africa

  • LAB International inked a transaction with Janssen Pharmaceutica related to LAB’s treatment of breakthrough cancer pain.  Fentanyl Taifun® is a fast-acting fentanyl formulation that uses the company's Taifun dry powder inhaler currently in Phase II development.

    Under the terms of this licensing and development agreement, LAB will receive a signing fee of $10.8 million, up to $33.6 million in development and regulatory milestones, and payments of commercial sales milestones. LAB says that it could receive significant royalty income on sales of the product as well as manufacturing profit.

    LAB and Janssen Pharmaceutica will collaborate on development of the product as a therapy for breakthrough cancer pain. The licensing deal covers the EU, Eastern Europe, Russia, the Middle-East, and Africa. Janssen Pharmaceutica will be the marketing authorization holder in these territories. LAB will manufacture the product for all territories. Janssen Pharmaceutica will be responsible for developing any additional indications.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »